Table of Contents
Molecular Biology International
Volume 2014 (2014), Article ID 852748, 9 pages
http://dx.doi.org/10.1155/2014/852748
Review Article

Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications

1Department of Medical Oncology, Dr. B. R. A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi 110029, India
2Department of Anaesthesia and Intensive Care Unit, Indraprastha Apollo Hospital, New Delhi 110076, India

Received 28 May 2014; Revised 18 August 2014; Accepted 19 August 2014; Published 7 September 2014

Academic Editor: Jamboor Vishwanatha

Copyright © 2014 Nida Iqbal and Naveed Iqbal. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. J. Riese and D. F. Stern, “Specificity within the EGF family/ErbB receptor family signaling network,” BioEssays, vol. 20, pp. 41–48, 1998. View at Google Scholar
  2. P. van der Geer, T. Hunter, and R. A. Lindberg, “Receptor protein-tyrosine kinases and their signal transduction pathways,” Annual Review of Cell Biology, vol. 10, pp. 251–337, 1994. View at Publisher · View at Google Scholar · View at Scopus
  3. G. Carpenter, L. King Jr., and S. Cohen, “Epidermal growth factor stimulates phosphorylation in membrane preparations in vitro,” Nature, vol. 276, no. 5686, pp. 409–410, 1978. View at Publisher · View at Google Scholar · View at Scopus
  4. L. C. Padhy, C. Shih, D. Cowing, R. Finkelstein, and R. A. Weinberg, “Identification of a phosphoprotein specifically induced by the transforming DNA of rat neuroblastomas,” Cell, vol. 28, no. 4, pp. 865–871, 1982. View at Publisher · View at Google Scholar · View at Scopus
  5. A. L. Schechter, D. F. Stern, L. Vaidyanathan et al., “The neu oncogene: An erb-B-related gene encoding a 185,000-Mr tumour antigen,” Nature, vol. 312, no. 5994, pp. 513–516, 1984. View at Publisher · View at Google Scholar · View at Scopus
  6. P. W. Brandt-Rauf, M. R. Pincus, and W. P. Carney, “The c-erbB-2 protein in oncogenesis: molecular structure to molecular epidemiology,” Critical Reviews in Oncogenesis, vol. 5, no. 2-3, pp. 313–329, 1994. View at Publisher · View at Google Scholar · View at Scopus
  7. M. A. Olayioye, “Update on HER-2 as a target for cancer therapy: intracellular signaling pathways of ErbB2/HER-2 and family members,” Breast Cancer Research, vol. 3, no. 6, pp. 385–389, 2001. View at Google Scholar
  8. R. M. Neve, H. A. Lane, and N. E. Hynes, “The role of overexpressed HER2 in transformation,” Annals of Oncology, vol. 12, supplement 1, pp. S9–S13, 2001. View at Publisher · View at Google Scholar · View at Scopus
  9. S. Ménard, S. M. Pupa, M. Campiglio, and E. Tagliabue, “Biologic and therapeutic role of HER2 in cancer,” Oncogene, vol. 22, no. 43, pp. 6570–6578, 2003. View at Publisher · View at Google Scholar · View at Scopus
  10. A. Citri and Y. Yarden, “EGF-ERBB signalling: towards the systems level,” Nature Reviews Molecular Cell Biology, vol. 7, no. 7, pp. 505–516, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. M. M. Moasser, “The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis,” Oncogene, vol. 26, no. 45, pp. 6469–6487, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. R. Nahta, L. X. H. Yuan, B. Zhang, R. Kobayashi, and F. J. Esteva, “Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells,” Cancer Research, vol. 65, no. 23, pp. 11118–11128, 2005. View at Google Scholar · View at Scopus
  13. L. Fornaro, M. Lucchesi, C. Caparello et al., “Anti-HER agents in gastric cancer: from bench to bedside,” Nature Reviews Gastroenterology and Hepatology, vol. 8, no. 7, pp. 369–383, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. P. P. Di Fiore, J. H. Pierce, M. H. Kraus, O. Segatto, C. R. King, and S. A. Aaronson, “erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells,” Science, vol. 237, no. 4811, pp. 178–182, 1987. View at Publisher · View at Google Scholar · View at Scopus
  15. W. J. Muller, E. Sinn, P. K. Pattengale, R. Wallace, and P. Leder, “Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene,” Cell, vol. 54, no. 1, pp. 105–115, 1988. View at Publisher · View at Google Scholar · View at Scopus
  16. H. J. Burstein, “The distinctive nature of HER2-positive breast cancers,” The New England Journal of Medicine, vol. 353, no. 16, pp. 1652–1654, 2005. View at Publisher · View at Google Scholar · View at Scopus
  17. S. I. Fukushige, K. I. Matsubara, M. Yoshida et al., “Localization of a novel v-erbB-related gene, c-erbB-2, on human chromosome 17 and its amplification in a gastric cancer cell line,” Molecular and Cellular Biology, vol. 6, no. 3, pp. 955–958, 1986. View at Google Scholar · View at Scopus
  18. U. Reichelt, P. Duesedau, M. Ch. Tsourlakis et al., “Frequent homogenous HER-2 amplification in primary and metastatic adenocarcinomas of the esophagus,” Modern Pathology, vol. 20, no. 1, pp. 120–129, 2007. View at Google Scholar
  19. O.-P. Kallioniemi, A. Kallioniemi, W. Kurisu et al., “ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization,” Proceedings of the National Academy of Sciences of the United States of America, vol. 89, no. 12, pp. 5321–5325, 1992. View at Publisher · View at Google Scholar · View at Scopus
  20. J. Shou, S. Massarweh, C. K. Osborne et al., “Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer,” Journal of the National Cancer Institute, vol. 96, no. 12, pp. 926–935, 2004. View at Publisher · View at Google Scholar · View at Scopus
  21. M. A. Molina, R. Sáez, E. E. Ramsey et al., “NH2-terminal truncated HER-2 protein but not full-length receptor is associated with nodal metastasis in human breast cancer,” Clinical Cancer Research, vol. 8, no. 2, pp. 347–353, 2002. View at Google Scholar · View at Scopus
  22. M. Scaltriti, F. Rojo, A. Ocaña et al., “Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer,” Journal of the National Cancer Institute, vol. 99, no. 8, pp. 628–638, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. D. J. Slamon, G. M. Clark, S. G. Wong, W. J. Levin, A. Ullrich, and W. L. McGuire, “Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene,” Science, vol. 235, no. 4785, pp. 177–182, 1987. View at Google Scholar
  24. M. F. Press, M. C. Pike, V. R. Chazin et al., “Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease,” Cancer Research, vol. 53, no. 20, pp. 4960–4970, 1993. View at Google Scholar · View at Scopus
  25. R. Seshadri, F. A. Firgaira, D. J. Horsfall, K. McCaul, V. Setlur, and P. Kitchen, “Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group,” Journal of Clinical Oncology, vol. 11, no. 10, pp. 1936–1942, 1993. View at Google Scholar · View at Scopus
  26. K. Park, S. Han, H. J. Kim, J. Kim, and E. Shin, “HER2 status in pure ductal carcinoma in situ and in the intraductal and invasive components of invasive ductal carcinoma determined by fluorescence in situ hybridization and immunohistochemistry,” Histopathology, vol. 48, no. 6, pp. 702–707, 2006. View at Publisher · View at Google Scholar · View at Scopus
  27. Z. Gabos, R. Sinha, J. Hanson et al., “Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer,” Journal of Clinical Oncology, vol. 24, no. 36, pp. 5658–5663, 2006. View at Publisher · View at Google Scholar · View at Scopus
  28. K. Sakai, S. Mori, T. Kawamoto et al., “Expression of epidermal growth factor receptors on normal human gastric epithelia and gastric carcinomas,” National Cancer Institute, vol. 77, no. 5, pp. 1047–1052, 1986. View at Google Scholar
  29. T. Yano, A. Ochiai, T. Doi et al., “Expression of HER2 in gastric cancer: comparison between protein expression and gene amplification using a new commercial kit,” Journal of Clinical Oncology, vol. 22, article 14S, abstract 4053, 2004. View at Google Scholar
  30. C. Gravalos and A. Jimeno, “HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target,” Annals of Oncology, vol. 19, no. 9, pp. 1523–1529, 2008. View at Publisher · View at Google Scholar · View at Scopus
  31. Y.-J. Bang, E. van Cutsem, A. Feyereislova et al., “Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial,” The Lancet, vol. 376, no. 9742, pp. 687–697, 2010. View at Publisher · View at Google Scholar · View at Scopus
  32. M. Tanner, M. Hollmen, T. T. Junttila et al., “Amplification of HER-2 in gastric carcinoma: association with topoisomerase IIa gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab,” Annals of Oncology, vol. 16, pp. 273–278, 2005. View at Publisher · View at Google Scholar
  33. Y. Yonemura, I. Ninomiya, A. Yamaguchi et al., “Evaluation of immunoreactivity for erbB-2 protein as a marker of poor short-term prognosis in gastric cancer,” Cancer Research, vol. 51, no. 3, pp. 1034–1038, 1991. View at Google Scholar
  34. S. Uchino, H. Tsuda, K. Maruyama et al., “Overexpression of c-erbB-2 protein in gastric cancer. Its correlation with long-term survival of patients,” Cancer, vol. 72, no. 11, pp. 3179–3184, 1993. View at Google Scholar
  35. M. Nakajima, H. Sawada, Y. Yamada et al., “The prognostic significance of amplification and overexpression of c-met and c-erbB-2 in human gastric carcinomas,” Cancer, vol. 85, pp. 1894–1902, 1999. View at Google Scholar
  36. J.-F. Flejou, F. Paraf, F. Muzeau et al., “Expression of c-erbB-2 oncogene product in Barrett's adenocarcinoma: pathological and prognostic correlations,” Journal of Clinical Pathology, vol. 47, no. 1, pp. 23–26, 1994. View at Publisher · View at Google Scholar · View at Scopus
  37. H. Safran, T. DiPetrillo, A. Nadeem et al., “Trastuzumab, paclitaxel, cisplatin, and radiation for adenocarcinoma of the esophagus: a phase I study,” Cancer Investigation, vol. 22, no. 5, pp. 670–677, 2004. View at Publisher · View at Google Scholar · View at Scopus
  38. Z. Suo, W. Su, R. Holm, and J. M. Nesland, “Lack of expression of c-erbB-2 oncoprotein in human esophageal squamous cell carcinomas,” Anticancer Research, vol. 15, no. 6B, pp. 2797–2798, 1995. View at Google Scholar · View at Scopus
  39. M. Akamatsu, T. Matsumoto, K. Oka et al., “C-erbB-2 oncoprotein expression related to chemoradioresistance in esophageal squamous cell carcinoma,” International Journal of Radiation Oncology Biology Physics, vol. 57, no. 5, pp. 1323–1327, 2003. View at Publisher · View at Google Scholar · View at Scopus
  40. H. H. Yoon, Q. Shi, W. R. Sukov et al., “Association of HER2/ErbB2 expression and gene amplification with pathologic features and prognosis in esophageal adenocarcinomas,” Clinical Cancer Research, vol. 18, no. 2, pp. 546–554, 2012. View at Publisher · View at Google Scholar · View at Scopus
  41. H. H. Yoon, Q. Shi, W. R. Sukov et al., “Adverse prognostic impact of intratumor heterogeneous HER2 gene amplification in patients with esophageal adenocarcinoma,” Journal of Clinical Oncology, vol. 30, no. 32, pp. 3932–3938, 2012. View at Publisher · View at Google Scholar · View at Scopus
  42. N. Zhan, W.-G. Dong, Y.-F. Tang, Z.-S. Wang, and C.-L. Xiong, “Analysis of HER2 gene amplification and protein expression in esophageal squamous cell carcinoma,” Medical Oncology, vol. 29, no. 2, pp. 933–940, 2012. View at Publisher · View at Google Scholar · View at Scopus
  43. A. Berchuck, A. Kamel, R. Whitaker et al., “Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer,” Cancer Research, vol. 50, no. 13, pp. 4087–4091, 1990. View at Google Scholar · View at Scopus
  44. J. M. S. Bartlett, S. P. Langdon, B. J. B. Simpson et al., “The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer,” British Journal of Cancer, vol. 73, no. 3, pp. 301–306, 1996. View at Publisher · View at Google Scholar · View at Scopus
  45. C. D. Rolitsky, K. S. Theil, V. R. McGaughy, L. J. Copeland, and T. H. Niemann, “HER-2/neu amplification and overexpression in endometrial carcinoma,” International Journal of Gynecological Pathology, vol. 18, no. 2, pp. 138–143, 1999. View at Google Scholar · View at Scopus
  46. C. Morrison, V. Zanagnolo, N. Ramirez et al., “HER-2 is an independent prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patients,” Journal of Clinical Oncology, vol. 24, no. 15, pp. 2376–2385, 2006. View at Publisher · View at Google Scholar · View at Scopus
  47. T. A. Grushko, V. L. Filiaci, A. J. Mundt, K. Ridderstråle, O. I. Olopade, and G. F. Fleming, “An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: a gynecologic oncology group study,” Gynecologic Oncology, vol. 108, no. 1, pp. 3–9, 2008. View at Publisher · View at Google Scholar · View at Scopus
  48. A. D. Santin, S. Bellone, S. van Stedum et al., “Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma,” Cancer, vol. 104, no. 7, pp. 1391–1397, 2005. View at Publisher · View at Google Scholar · View at Scopus
  49. P. A. Bunn Jr., B. Helfrich, A. F. Soriano et al., “Expression of Her-2/neu in human lung cancer cell lines by immunohistochemistry and fluorescence in situ hybridization and its relationship to in vitro cytotoxicity by trastuzumab and chemotherapeutic agents,” Clinical Cancer Research, vol. 7, no. 10, pp. 3239–3250, 2001. View at Google Scholar
  50. P. Heinmöller, C. Gross, K. Beyser et al., “HER2 status in non-small cell lung cancer: results from patient screening for enrollment to a phase II study of herceptin,” Clinical Cancer Research, vol. 9, no. 14, pp. 5238–5244, 2003. View at Google Scholar · View at Scopus
  51. P. Stephens, C. Hunter, G. Bignell et al., “Lung cancer: intragenic ERBB2 kinase mutations in tumours,” Nature, vol. 431, pp. 525–526, 2004. View at Google Scholar
  52. H. Shigemetsu, T. Takahashi, M. Nomura et al., “Somatic mutations of the HER2 kinase domain in lung adenocarcinomas,” Cancer Research, vol. 65, article 1642, 2005. View at Google Scholar
  53. Z. Latif, A. D. Watters, I. Dunn, K. M. Grigor, M. Underwood, and J. Bartlett, “HER2/neu overexpression in the development of muscle-invasive transitional cell carcinoma of the bladder,” British Journal of Cancer, vol. 89, no. 7, pp. 1305–1309, 2003. View at Publisher · View at Google Scholar · View at Scopus
  54. C. L. Coogan, C. R. Estrada, S. Kapur, and K. J. Bloom, “HER-2/neu protein overexpression and gene amplification in human transitional cell carcinoma of the bladder,” Urology, vol. 63, pp. 786–790, 2004. View at Google Scholar
  55. C. J. Langer, P. Stephenson, A. Thor, M. Vangel, and D. H. Johnson, “Trastuzumab in the treatment of advanced non-small-cell lung cancer: is there a role? Focus on Eastern Cooperative Oncology Group Study 2598,” Journal of Clinical Oncology, vol. 22, no. 7, pp. 1180–1187, 2004. View at Publisher · View at Google Scholar · View at Scopus
  56. M. H. Hussain, G. R. MacVicar, D. P. Petrylak et al., “Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial,” Journal of Clinical Oncology, vol. 25, no. 16, pp. 2218–2224, 2007. View at Google Scholar
  57. AC. Wolff, M. E. H. Hammond, D. G. Hicks et al., “Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update,” Journal Clinical Oncology, 2013. View at Publisher · View at Google Scholar
  58. A. C. Wolff, M. E. Hammond, J. N. Schwartz et al., “American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer,” Journal of Clinical Oncology, vol. 25, no. 1, pp. 118–145, 2007. View at Google Scholar
  59. S. Ménard, E. Tagliabue, M. Campiglio, and S. M. Pupa, “Role of HER2 gene overexpression in breast carcinoma,” Journal of Cellular Physiology, vol. 182, no. 2, pp. 150–162, 2000. View at Google Scholar
  60. M. Hofmann, O. Stoss, D. Shi et al., “Assessment of a HER2 scoring system for gastric cancer: results from a validation study,” Histopathology, vol. 52, no. 7, pp. 797–805, 2008. View at Publisher · View at Google Scholar · View at Scopus
  61. J. Rüschoff, M. Dietel, G. Baretton et al., “HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing,” Virchows Archiv, vol. 457, no. 3, pp. 299–307, 2010. View at Publisher · View at Google Scholar · View at Scopus
  62. T. Kute, C. M. Lack, M. Willingham et al., “Development of Herceptin Resistance in Breast Cancer Cells,” Cytometry A, vol. 57, no. 2, pp. 86–93, 2004. View at Google Scholar · View at Scopus
  63. E. H. Romond, E. A. Perez, J. Bryant et al., “Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer,” New England Journal of Medicine, vol. 353, no. 16, pp. 1673–1684, 2005. View at Publisher · View at Google Scholar · View at Scopus
  64. M. J. Piccart-Gebhart, M. Procter, B. Leyland-Jones et al., “Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer,” The New England Journal of Medicine, vol. 353, no. 16, pp. 1659–1672, 2005. View at Publisher · View at Google Scholar · View at Scopus
  65. D. Slamon, W. Eiermann, N. Robert et al., “Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC/T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC/TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study,” Breast Cancer Research and Treatment, vol. 94, supplement 1, p. S1, 2005. View at Google Scholar
  66. H. Joensuu, P.-L. Kellokumpu-Lehtinen, P. Bono et al., “Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer,” New England Journal of Medicine, vol. 354, no. 8, pp. 809–820, 2006. View at Publisher · View at Google Scholar · View at Scopus
  67. D. J. Slamon, B. Leyland-Jones, S. Shak et al., “Use of chemotherapy plus a monoclonal antibody against her2 for metastatic breast cancer that overexpresses HER2,” The New England Journal of Medicine, vol. 344, no. 11, pp. 783–792, 2001. View at Publisher · View at Google Scholar · View at Scopus
  68. Y.-J. Bang, E. Van Cutsem, A. Feyereislova et al., “Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial,” The Lancet, vol. 376, no. 9742, pp. 687–697, 2010. View at Publisher · View at Google Scholar · View at Scopus
  69. C. E. Geyer, J. Forster, D. Lindquist et al., “Lapatinib plus capecitabine for HER2-positive advanced breast cancer,” The New England Journal of Medicine, vol. 355, no. 26, pp. 2733–2743, 2006. View at Google Scholar
  70. L. S. Schwartzberg, S. X. Franco, A. Florance, L. O'Rourke, J. Maltzman, and S. Johnston, “Lapatinib plus letrozole as first-line therapy for HER-2+ hormone receptor-positive metastatic breast cancer,” Oncologist, vol. 15, no. 2, pp. 122–129, 2010. View at Google Scholar
  71. J. Baselga, J. Cortés, S.-B. Kim et al., “Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer,” The New England Journal of Medicine, vol. 366, no. 2, pp. 109–119, 2012. View at Publisher · View at Google Scholar · View at Scopus
  72. L. Gianni, T. Pienkowski, Y.-H. Im et al., “Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial,” The Lancet Oncology, vol. 13, no. 1, pp. 25–32, 2012. View at Publisher · View at Google Scholar · View at Scopus
  73. S. Verma, D. Miles, L. Gianni et al., “Trastuzumab emtansine for HER2-positive advanced breast cancer,” The New England Journal of Medicine, vol. 367, no. 19, pp. 1783–1791, 2012. View at Publisher · View at Google Scholar · View at Scopus
  74. H. J. Burstein, Y. Sun, L. Y. Dirix et al., “Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer,” Journal of Clinical Oncology, vol. 28, no. 8, pp. 1301–1307, 2010. View at Publisher · View at Google Scholar · View at Scopus
  75. N. U. Lin, E. P. Winer, D. Wheatley et al., “A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab,” Breast Cancer Research and Treatment, vol. 133, no. 3, pp. 1057–1065, 2012. View at Publisher · View at Google Scholar · View at Scopus
  76. N. Harbeck, S.-A. Im, C. S. Huang et al., “LUX-breast 1: randomized, phase III trial of afatinib and vinorelbine versus trastuzumab and vinorelbine in patients with HER2-overexpressing metastatic breast cancer (MBC) failing one prior trastuzumab treatment,” Journal of Clinical Oncology, vol. 30, abstract TPS649, 2012. View at Google Scholar